HAVCR2 and acute myeloid leukemia: Therefore, TIM3 blockade has been proposed as an immune-checkpoint inhibitor (ICI), and there are ongoing clinical trials in advanced metastatic disease for acute myeloid leukemia (AML),16 lung cancer,17 and melanoma.18